| Product Unit Size | Cost | Quantity | Stock |
|---|
Iniparib was initially discovered as an inhibitor of poly(ADP-ribose) polymerase (PARP 1), but has since been found to only weakly modulate PARP in an indirect manner. The exact mechanism of iniparib is unknown, but it is known to form adducts with cysteine-containing proteins. In vitro, iniparib inhibited single-stranded DNA break repair mechanisms. Clinical trials of this compound have shown mixed results in the treatment of cancers.
| Cas No. | 160003-66-7 |
|---|---|
| Purity | ≥98% |
| Formula | C7H5IN2O3 |
| Formula Wt. | 292.03 |
| IUPAC Name | 4-iodo-3-nitrobenzamide |
| Synonym | IND 71677; BSI-201 |
| Appearance | Yellow Solid |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Mateo J, Ong M, Tan DS, et al. Appraising iniparib, the PARP inhibitor that never was-what must we learn? Nat Rev Clin Oncol. 2013 Dec;10(12):688-96. PMID: 24129347.
Wilkinson-Ryan I, Mutch D. A review of iniparib in ovarian cancer. Expert Opin Investig Drugs. 2013 Mar;22(3):399-405. PMID: 23394483.
Ma W, Halweg CJ, Menendez D, et al. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6590-5. PMID: 22493268
Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012 Jan 15;18(2):510-23. PMID: 22128301.